DE60132337D1 - Nicht-sedierende barbituratverbindungen als neuroprotektive wirkstoffe - Google Patents

Nicht-sedierende barbituratverbindungen als neuroprotektive wirkstoffe

Info

Publication number
DE60132337D1
DE60132337D1 DE60132337T DE60132337T DE60132337D1 DE 60132337 D1 DE60132337 D1 DE 60132337D1 DE 60132337 T DE60132337 T DE 60132337T DE 60132337 T DE60132337 T DE 60132337T DE 60132337 D1 DE60132337 D1 DE 60132337D1
Authority
DE
Germany
Prior art keywords
seding
active substances
barbiturate
sedative
barbiturate compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60132337T
Other languages
English (en)
Other versions
DE60132337T2 (de
Inventor
Daniel A Moros
Barrie Levitt
Avraham Yacobi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taro Pharmaceutical Industries Ltd
Original Assignee
Taro Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharmaceutical Industries Ltd filed Critical Taro Pharmaceutical Industries Ltd
Application granted granted Critical
Publication of DE60132337D1 publication Critical patent/DE60132337D1/de
Publication of DE60132337T2 publication Critical patent/DE60132337T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
DE60132337T 2000-07-26 2001-07-26 Nicht-sedierende barbituratverbindungen als neuroprotektive wirkstoffe Expired - Lifetime DE60132337T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22167200P 2000-07-26 2000-07-26
US221672P 2000-07-26
PCT/US2001/023420 WO2002007729A1 (en) 2000-07-26 2001-07-26 Non-sedating barbiturate compounds as neuroprotective agents

Publications (2)

Publication Number Publication Date
DE60132337D1 true DE60132337D1 (de) 2008-02-21
DE60132337T2 DE60132337T2 (de) 2009-02-12

Family

ID=22828824

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60132337T Expired - Lifetime DE60132337T2 (de) 2000-07-26 2001-07-26 Nicht-sedierende barbituratverbindungen als neuroprotektive wirkstoffe

Country Status (14)

Country Link
EP (1) EP1311270B1 (de)
JP (1) JP5047442B2 (de)
CN (2) CN100522172C (de)
AT (1) ATE383159T1 (de)
AU (2) AU2001280778B2 (de)
BR (1) BR0112775A (de)
CA (1) CA2416535C (de)
DE (1) DE60132337T2 (de)
ES (1) ES2300349T3 (de)
HK (1) HK1100814A1 (de)
IL (3) IL154060A0 (de)
MX (1) MXPA03000824A (de)
PT (1) PT1311270E (de)
WO (1) WO2002007729A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093820A (en) 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
CN100522172C (zh) * 2000-07-26 2009-08-05 塔罗制药工业有限公司 非镇静巴比土酸盐化合物在制备神经保护剂中的用途
US6939873B2 (en) 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
WO2003063872A1 (en) * 2002-01-30 2003-08-07 Taro Pharmaceutical Industries Ltd. Non-sedating barbituric acid derivatives
AU2003282464B2 (en) * 2002-10-11 2010-02-25 Baxter International, Inc. Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics
TW200822927A (en) 2002-12-11 2008-06-01 Taro Pharmaceuticals Ireland Ltd Method of treating movement disorders using barbituric acid derivatives
EP1625848A1 (de) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Zusammensetzung und Verfahren zur verbesserten Abgabe von 5,5-Diphenylbarbitursäure
EP2755945A1 (de) * 2011-09-12 2014-07-23 Council of Scientific & Industrial Research Arylierte beta-dicarbonylverbindungen und verfahren zu ihrer herstellung
CN102863579B (zh) * 2012-09-14 2014-02-05 东南大学 一种巴比妥酸螯合树脂及其制备方法和应用
EP3329279B1 (de) 2015-10-05 2021-07-07 The University of North Carolina at Chapel Hill Decodierungsverfahren für multiplex-assays und zugehörige fluidische vorrichtungen, kits und feste träger

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69722A (en) * 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
US4833148A (en) * 1987-04-09 1989-05-23 Washington University Method of using alkenyl- or alkynyl-substituted thiobarbiturates to reduce neurotoxic injury
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
CN100522172C (zh) * 2000-07-26 2009-08-05 塔罗制药工业有限公司 非镇静巴比土酸盐化合物在制备神经保护剂中的用途

Also Published As

Publication number Publication date
WO2002007729A1 (en) 2002-01-31
CA2416535A1 (en) 2002-01-31
MXPA03000824A (es) 2004-11-01
EP1311270A1 (de) 2003-05-21
IL154060A0 (en) 2003-07-31
CA2416535C (en) 2010-11-16
DE60132337T2 (de) 2009-02-12
EP1311270B1 (de) 2008-01-09
BR0112775A (pt) 2003-12-30
EP1311270A4 (de) 2006-04-12
AU8077801A (en) 2002-02-05
ATE383159T1 (de) 2008-01-15
CN100522172C (zh) 2009-08-05
CN1329032C (zh) 2007-08-01
IL154060A (en) 2013-05-30
CN1872067A (zh) 2006-12-06
HK1100814A1 (en) 2007-09-28
ES2300349T3 (es) 2008-06-16
IL165017A0 (en) 2005-12-18
AU2001280778B2 (en) 2004-09-02
JP2004517808A (ja) 2004-06-17
WO2002007729A9 (en) 2002-08-08
JP5047442B2 (ja) 2012-10-10
CN1461219A (zh) 2003-12-10
PT1311270E (pt) 2008-04-15

Similar Documents

Publication Publication Date Title
HK1100814A1 (en) Use of non-sedating barbiturate compounds in preparation of neuroprotective agents
DE60021570D1 (de) Neue zubereitung und darreichungsform enthaltend einen säurelabilen protonenpumpeninhibitor
NZ509418A (en) Pharmaceutical formulations for aerosols with two or more active substances
ATE252899T1 (de) Schilddrüsenhormone enthaltende mittel
SE0202857D0 (sv) Method and compositions for preventing hormone induced adverse effects
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
MXPA02007690A (es) Composiciones de liberacion controlada que contienen agonista y antiagonista de opioide.
IS1889B (is) Innöndunarefnasambönd
ECSP045238A (es) Forma de dosis oral que contiene un inhibidor de pde 4 como un ingrediente activo y polivinilpirrolidona como excipiente
AR012172A2 (es) Composiciones farmaceuticas que comprenden analogos de lactacistina y uso de los mismos para la fabricacion de un medicamento
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
BR0314898A (pt) Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica
PT1207756E (pt) Utilizacao de espinosade ou de uma formulacao que compreende espinosade
DE60022895D1 (de) Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
DE69520292T2 (de) Pharmazeutische zubereitung zur direktverpressung
WO2006009602A3 (en) Multiple ppi dosage form
ATE400256T1 (de) Pharmazeutische zusammensetzung mit einem kationischen hilfsmittel
DE69803670D1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
EP1905441A3 (de) Nicht-sedierende Barbituratverbindungen als neuroprotektive Wirkstoffe
PE20020903A1 (es) Metodo para prevenir la diarrea
DE60112584D1 (de) Verfahren zur Herstellung einer flüssigen Dosierungseinheit und Kit
CO5580753A2 (es) Composicion farmaceutica que comprende un antagonista ltb4 y un inhibidor cox-2 o un inhibidor cox1/2
Winston et al. Pharmacokinetics of Ganciclovir Following Oral Valganciclovir Versus Intravenous Ganciclovir in Allogeneic Hematopoietic Stem-Cell Transplant Patients with Stable Graft-Versus-Host Disease of the Gastrointestinal Tract.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition